Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. reports news tied to its spatial biology business, including spatial proteomics platforms, multiplex immunofluorescence assays and cancer research collaborations. Company updates have covered the PhenoCycler-Fusion platform, PhenoCode Discovery IO60 panel, single-cell spatial proteomics data resources, immuno-oncology studies and biopharma service offerings for biomarker and translational research.
Akoya news also includes operating and financial results, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. In July 2025, Akoya completed a merger and became a wholly owned subsidiary of Quanterix, making its AKYA public-company news record relevant as historical reference for the former Nasdaq-listed issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Akoya Biosciences (Nasdaq: AKYA) announced the shipment of its 1,000th instrument, marking a significant milestone and establishing the largest installed base in the spatial biology industry. This achievement highlights the widespread adoption of Akoya's technologies in research laboratories globally and sets the stage for clinical applications. The portfolio features advanced tools such as PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT, enabling precise spatial biomarker identification. CEO Brian McKelligon expressed gratitude to the team for their role in this success and reiterated the commitment to expanding their ecosystem of spatial biology solutions. The 1,000th system was delivered to iHisto, a histopathology lab known for high-quality services and innovative technologies.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCode Discovery Panels at the AACR 2023 Annual Meeting in Orlando, aimed at advancing cancer research. These panels facilitate the analysis of tumors and their microenvironment by providing ready-to-use biomarker combinations for immune profiling and tissue architecture assessment. They significantly reduce assay development time, accelerating spatial discovery by up to three times compared to traditional workflows. The company plans to expand its product offerings with more protein biomarker panels throughout 2023 and 2024, along with launching RNA panels in the latter half of 2023. Akoya's innovations aim to streamline workflows for researchers and enhance the capabilities of the PhenoCycler-Fusion platform.